Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort

Autoimmunity Reviews

Volumn 13, Issue 12, 2014, Pages 1211-1219

  Bodoki, Levente ^a   Nagy Vincze, Melinda ^a   Griger, Zoltán ^a   Betteridge, Zoe ^b   Szöllosi, Lászlóné ^a   Dankó, Katalin ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

Author keywords

Anti NXP2; Anti SAE; Anti TIF1 ; Idiopathic inflammatory myopathy; Myositis specific autoantibodies

Indexed keywords

AUTOANTIBODY; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 ANTIBODY; NUCLEAR MATRIX PROTEIN 2 ANTIBODY; SMALL UBIQUITIN LIKE MODIFIER ACTIVATING ENZYME ANTIBODY; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1 GAMMA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTHRALGIA; COHORT ANALYSIS; DERMATOMYOSITIS; DISEASE COURSE; DYSPHAGIA; DYSPHONIA; DYSPNEA; HUMAN; JUVENILE; JUVENILE DERMATOMYOSITIS; LUNG FIBROSIS; MANUAL MUSCLE TESTING; MEDICAL HISTORY; MUSCLE EXAMINATION; MYOSITIS; RETROSPECTIVE STUDY; REVIEW; SKIN ULCER; ADOLESCENT; HUNGARY; IMMUNOLOGY; PROGNOSIS;

ADOLESCENT; ADULT; AUTOANTIBODIES; COHORT STUDIES; DERMATOMYOSITIS; DISEASE PROGRESSION; HUMANS; HUNGARY; MYOSITIS; PROGNOSIS;

EID: 84908880196     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.011     Document Type: Review

References (66)

1. Bohan A., Peter J.B. Polymyositis and dermatomyositis. N Engl J Med 1975, 292:344-347.
2. Mastaglia F.L., Phillips B.A. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am Nov 2002, 28(4):723-741.
3. Sun C., Lee J.H., Yang Y.H., Yu H.H., Wang L.C., Lin Y.T., et al. Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes. Pediatr Neonatol Jun 27 2014, [in press, pii: S1875-9572(14)00093-X].
4. Luo Y.B., Mastaglia F.L. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta Jun 5 2014, [in press, pii: S0925-4439(14)00162-8].
5. Catalán M., Selva-O'Callaghan A., Grau J.M. Diagnosis and classification of sporadic inclusion body myositis (sIBM). Autoimmun Rev Apr-May 2014, 13(4-5):363-366.
6. Neri R., Barsotti S., Iacopetti V., Tripoli A., d'Ascanio A., Tavoni A.G., et al. Clinically amyopathic dermatomyositis: analysis of a monocentric cohort. J Clin Neuromuscul Dis Jun 2014, 15(4):157-160.
7. Dankó K., Ponyi A., Molnar A.P., András C., Constantin T. Paraneoplastic myopathy. Curr Opin Rheumatol Nov 2009, 21(6):594-598.
8. Dalakas M.C. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev Jan 2012, 11(3):203-206.
9. Prieto-González S., Grau J.M. Diagnosis and classification of granulomatous myositis. Autoimmun Rev Apr-May 2014, 13(4-5):372-374.
10. Selva-O'Callaghan A., Trallero-Araguás E., Grau J.M. Eosinophilic myositis: an updated review. Autoimmun Rev Apr-May 2014, 13(4-5):375-378.
11. Mahler M., Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev Aug 2007, 6(7):432-437.
12. Yan J., Wu P. Idiopathic orbital myositis. J Craniofac Surg May 2014, 25(3):884-887.
13. Matsuse D., Ikezoe K., Shigeto H., Murai H., Ohyagi Y., Kira J. Case of eosinophilic myositis in continuum from localized nodular myositis. Rinsho Shinkeigaku Jan 2008, 48(1):36-42. [Article in Japanese].
14. Michaelides S.A., Passalidou E., Bablekos G.D., Aza E., Goulas G., Chorti M., et al. Cavitating lung lesion as a manifestation of inflammatory tumor (pseudotumor) of the lung: a case report and literature review. Am J Case Rep Jun 17 2014, 15:258-265.
15. Stübgen J.P. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev Jan 2014, 13(1):31-39.
16. Vajsar J., Jay V., Babyn P. Infantile myositis presenting in the neonatal period. Brain Dev Sep-Oct 1996, 18(5):415-419.
17. Dorph C., Lundberg I.E. Idiopathic inflammatory myopathies-myositis. Best Pract Res Clin Rheumatol 2002, 16:817-832.
18. Takeda Y., Wang G.S., Wang R.J., Anderson S.K., Pettersson I., Amaki S., et al. Enzyme-linked immunosorbent assay using isolated (U) small nuclear ribonucleoprotein polypeptides as antigens to investigate the clinical significance of autoantibodies to these polypeptides. Clin Immunol Immunopathol Feb 1989, 50(2):213-230.
19. La Corte R., Lo Mo Naco A., Locaputo A., Dolzani F., Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity May 2006, 39(3):249-253.
20. Váncsa A., Csípo I., Németh J., Dévényi K., Gergely L., Dankó K. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int Jul 2009, 29(9):989-994.
21. Wang J., Satoh M., Kabir F., Shaw M., Domingo M.A., Mansoor R., et al. Increased prevalence of autoantibodies to Ku antigen in African American versus white patients with systemic lupus erythematosus. Arthritis Rheum Oct 2001, 44(10):2367-2370.
22. Cooley H.M., Melny B.J., Gleeson R., Greco T., Kay T.W. Clinical and serological associations of anti-Ku antibody. J Rheumatol Mar 1999, 26(3):563-567.
23. Franceschini F., Cavazzana I., Generali D., Quinzanini M., Viardi L., Ghirardello A., et al. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J Rheumatol Jul 2002, 29(7):1393-1397.
24. Brouwer R., Hengstman G.J., Vree Egberts W., Ehrfeld H., Bozic B., Ghirardello A., et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis Feb 2001, 60(2):116-123.
25. Sugie K., Tonomura Y., Ueno S. Characterization of dermatomyositis with coexistence of anti-Jo-1 and anti-SRP antibodies. Intern Med 2012, 51(7):799-802.
26. Targoff I.N. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 2000, 12:475-481.
27. Lega J.C., Fabien N., Reynaud Q., Durieu I., Durupt S., Dutertre M., et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev Apr 3, 2014, [in press, pii: S1568-9972(14)00101-3].
28. Rojana-udomsart A., Mitrpant C., Bundell C., Price L., Luo Y.B., Fabian V., et al. Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM). J Neuroimmunol Nov 15 2013, 264(1-2):65-70.
29. Allenbach Y., Drouot L., Rigolet A., Charuel J.L., Jouen F., Romero N.B., et al. Anti-HMGCR Autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) May 2014, 93(3):150-157.
30. Christopher-Stine L., Casciola-Rosen L.A., Hong G., Chung T., Corse A.M., Mammen A.L. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum Sep 2010, 62(9):2757-2766.
31. Hamann P.D., Cooper R.G., McHugh N.J., Chinoy H. Statin-induced necrotizing myositis-a discrete autoimmune entity within the "statin-induced myopathy spectrum". Autoimmun Rev Okt 2013, 12(12):1177-1181.
32. Casciola-Rosen L., Mammen A.L. Myositis autoantibodies. Curr Opin Rheumatol Nov 2012, 24(6):602-608.
33. Tansley S.L., Betteridge Z.E., McHugh N.J. The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol 2013, 25:772-777.
34. Targoff I.N., Trieu E.P., Levy-Neto M., Fertig N., Oddis C.V. Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum 2007, 56:S787.
35. Hamaguchi Y., Kuwana M., Hoshino K., Hasegawa M., Kaji K., Matsushita T., et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011, 147:391-398.
36. Fiorentino D., Chung L., Zwerner J., Rosen A., Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011, 65:25-34.
37. http://www.orgentec.com/products/pdfs/IFU_ELISA_Blot_EN/ORG%20760_IFU_EN_QM113220_2012-11-27_1.1.pdf.
38. Rider L.G., Koziol D., Giannini E.H., Jain M.S., Smith M.R., Whitney-Mahoney K., et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010, 62:465-472.
39. Kendall F.P., McCreary E.K., Provance P.G. Muscles: testing and function 1993, Williams and Wilkins, Baltimore. 4th ed.
40. Mahler M., Miller F.W., Fritzler M.J. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev Apr-May 2014, 13(4-5):367-371.
41. Koneig M., Fritzler M.J., Targoff I.N., Troyanov Y., Senécal J.L. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007, 9(4):R78.
42. Hervier B., Devilliers H., Stanciu R., Meyer A., Uzunhan Y., Masseau A., et al. Hierarchical cluster and survival analyses of antisynthetase-syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev Dec 2012, 12(2):210-217.
43. Marie I., Josse S., Decaux O., Dominique S., Diot E., Landron C., et al. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev Aug 2012, 11(10):739-745.
44. Labirua-Iturburu A., Selva-O'Callaghan A., Vincze M., Dankó K., Vencovsky J., Fisher B., et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) Jul 2012, 91(4):206-211.
45. Ingegnoli F., Lubatti C., Ingegnoli A., Boracchi P., Zeni S., Meroni P.L. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in anti-Jo1 antibody-positive polymyositis patients: a single center study and review of the literature. Autoimmun Rev Mar 2012, 11(5):335-340.
46. Targoff I.N., Mamyrova G., Trieu E.P., Perurena O., Koneru B., O'Hanlon T.P., et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006, 54:3682-3689.
47. Kaji K., Fujimoto M., Hasegawa M., Kondo M., Saito Y., Komura K., et al. Identification of a novel autoantibody reactive with 155 and 140kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007, 46:25-28.
48. Gunawardena H., Wedderburn L.R., North J., Betteridge Z., Dunphy J., Chinoy H., et al. Clinical associations of autoantibodies to a p155/140kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008, 47:324-328.
49. Ohashi M., Shu E., Tokuzumi M., Fujioka K., Ishizuka T., Hara A., et al. Anti-p155/140 antibody-positive dermatomyositis with metastasis originating from an unknown site. Acta Derm Venereol 2011, 91:84-85.
50. Hoshino K., Muro Y., Sugiura K., Tomita Y., Nakashima R., Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 2010, 49:1726-1733.
51. Zahr Z.A., Baer A.N. Malignancy in myositis. Curr Rheumatol Rep 2011, 13:208-215.
52. Kasuya A., Hamaguchi Y., Fujimoto M., Tokura Y. TIF1γ-overexpressing, highly progressive endometrial carcinoma in a patient with dermato-myositis positive for malignancy-associated anti-p155/140 autoantibody. Acta Derm Venereol 2013, 93:715-716.
53. Ichimura Y., Matsushita T., Hamaguchi Y., Kaji K., Hasegawa M., Tanino Y. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012, 71:710-713.
54. Ceribelli A., Fredi M., Taraborelli M., Cavazzana I., Franceschini F., Quinzanini M. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012, 14:R97.
55. Gunawardena H., Wedderburn L.R., Chinoy H., Betteridge Z.E., North J., Ollier W.E., et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009, 60:1807-1814.
56. Espada G., Maldonado Cocco J.A., Fertig N., Oddis C.V. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009, 36:2547-2551.
57. Marie I., Guillevin L., Menard J.F., Hatron P.Y., Cherin P., Amoura Z., et al. Hematological malignancy associated with polymyositis and dermatomyositis. Autoimmun Rev Jul 2012, 11(9):615-620.
58. Ebert E.C. The gastrointestinal complications of myositis. Aliment Pharmacol Ther 2010, 31:359-365.
59. Voigt E., Griga T., Tromm A., Henschel M.G., Vorgerd M., May B. Polymyositis of the skeletal muscles as an extraintestinal complication in quiescent ulcerative colitis. Int J Colorectal Dis 1999, 14:304-307.
60. Lowry C.A., Pilkington C.A. Juvenile dermatomyositis: extra-muscular manifestations and their management. Curr Opin Rheumatol 2009, 21:575-580.
61. Betteridge Z.E., Gunawardena H., Chinoy H., North J., Ollier W.E., Cooper R.G., et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 2009, 68:1621-1625.
62. Betteridge Z., Gunawardena H., North J., Slinn J., McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007, 56:3132-3137.
63. Tarricone E., Ghirardello A., Rampudda M., Bassi N., Punzi L., Doria A. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods 2012, 384:128-134.
64. Muro Y., Sugiura K., Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity 2013, 46:279-284.
65. Sato S., Hirakata M., Kuwana M., Suwa A., Inada S., Mimori T., et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005, 52:1571-1576.
66. Sato S., Kuwana M., Fujita T., Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 2013, 23:496-502.